Kathryn Haviland
2019
Compensation breakdown
| Non-Equity Incentive Plan | $183,960 |
|---|---|
| Option Awards | $1,708,483 |
| Salary | $431,830 |
| Stock Awards | $757,750 |
| Other | $8,400 |
| Total | $3,090,423 |
Haviland received $1.7M in option awards, accounting for 55% of the total pay in 2019.
Haviland also received $184K in non-equity incentive plan, $431.8K in salary, $757.8K in stock awards and $8.4K in other compensation.
Rankings
In 2019, Kathryn Haviland's compensation ranked 3,970th out of 13,971 executives tracked by ExecPay. In other words, Haviland earned more than 71.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,970 out of 13,971 | 72nd |
Division Manufacturing | 1,433 out of 5,701 | 75th |
Major group Chemicals And Allied Products | 505 out of 2,200 | 77th |
Industry group Drugs | 426 out of 1,886 | 77th |
Industry Pharmaceutical Preparations | 324 out of 1,398 | 77th |
Pay ratio
| Kathryn Haviland's Pay | $3,090,423 |
|---|---|
| Median Employee's Pay | $360,897 |
| Pay Ratio | 9to 1 |
In 2019, the annual total compensation of Kathryn Haviland was $3,090,423.
The annual total compensation of the median employee at Blueprint Medicines was $360,897.
The ratio of Kathryn Haviland's pay to the pay of median employee was therefore 9 to one.
Haviland's colleagues
We found four more compensation records of executives who worked with Kathryn Haviland at Blueprint Medicines in 2019.